Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
Aromatase inhibitors
Fertility preservation
IVF
Oncofertility
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
16
07
2020
accepted:
18
11
2020
pubmed:
5
1
2021
medline:
24
6
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
Breast cancer is the most common cancer in reproductive age women, and treatment can affect fertility; however, there is often concern regarding the safety of increased estradiol (E We reviewed charts of women with breast cancer who contacted the FP patient navigator (PN) at Northwestern University from 01/2005-01/2018. Oncology and fertility outcome data were collected. Data were analyzed by Chi-square test or regression, as appropriate. Kaplan-Meier curves were used to examine breast cancer recurrence and survival. Statistical analyses were performed with SPSS IBM Statistics 26.0 for Windows. 332 patients were included, of which 157 (47.3%) underwent FP. Median days to treatment after consulting the PN was 35 in the FP group and 21 in non-FP (p < 0.05). Cancer recurrence was noted in 7 (4.7%) FP patients and 13 (7.9%) non-FP patients (NS), and mortality in 5 (3.2%) FP patients and 7 (4.2%) non-FP patients (NS). Within the FP group, no significant differences were found in recurrence or mortality based on ER status, age, BMI, peak E FP is safe and effective in breast cancer patients, regardless of receptor status; E
Identifiants
pubmed: 33392838
doi: 10.1007/s10549-020-06031-4
pii: 10.1007/s10549-020-06031-4
doi:
Substances chimiques
Letrozole
7LKK855W8I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-437Subventions
Organisme : NIH HHS
ID : P50 HD076188
Pays : United States
Organisme : NIH HHS
ID : P50 HD076188
Pays : United States
Références
Rodriguez-Wallberg KA, Oktay K (2010) Fertility preservation in women with breast cancer. Clin Obstet Gynecol 53(4):753. https://doi.org/10.1097/GRF.0b013e3181f96e00
doi: 10.1097/GRF.0b013e3181f96e00
pubmed: 21048442
pmcid: 3404603
Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M et al (2018) SEER cancer statistics review, 1975–2015. National Cancer Institute, Bethesda
Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ et al (2012) Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 118(6):1710–1717. https://doi.org/10.1002/cncr.26459
doi: 10.1002/cncr.26459
pubmed: 21887678
Shnorhavorian M, Harlan LC, Smith AW, Keegan THM, Lynch CF, Prasad PK et al (2015) Fertility preservation knowledge, counseling, and actions among adolescent and young adult patients with cancer: a population-based study. Cancer 121(19):3499–3506. https://doi.org/10.1002/cncr.29328
doi: 10.1002/cncr.29328
pubmed: 26214755
pmcid: 4734641
Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M et al (2017) The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod 32(5):1033–1045. https://doi.org/10.1093/humrep/dex027
doi: 10.1093/humrep/dex027
pubmed: 28333356
Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A (2018) Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat 167(3):761–769. https://doi.org/10.1007/s10549-017-4555-3
doi: 10.1007/s10549-017-4555-3
pubmed: 29098528
Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M et al (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174–4183. https://doi.org/10.1200/jco.2004.01.159
doi: 10.1200/jco.2004.01.159
pubmed: 15483028
Achille MA, Rosberger Z, Robitaille R, Lebel S, Gouin J-P, Bultz BD et al (2006) Facilitators and obstacles to sperm banking in young men receiving gonadotoxic chemotherapy for cancer: the perspective of survivors and health care professionals. Hum Reprod 21(12):3206–3216. https://doi.org/10.1093/humrep/del307
doi: 10.1093/humrep/del307
pubmed: 16887922
Crawshaw MA, Glaser AW, Hale JP, Sloper P (2009) Male and female experiences of having fertility matters raised alongside a cancer diagnosis during the teenage and young adult years. Eur J Cancer Care 18(4):381–390. https://doi.org/10.1111/j.1365-2354.2008.01003.x
doi: 10.1111/j.1365-2354.2008.01003.x
Yee S, Abrol K, McDonald M, Tonelli M, Liu KE (2012) Addressing oncofertility needs: views of female cancer patients in fertility preservation. J Psychosoc Oncol 30(3):331–346. https://doi.org/10.1080/07347332.2012.664257
doi: 10.1080/07347332.2012.664257
pubmed: 22571247
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. https://doi.org/10.1200/JCO.2013.49.2678
doi: 10.1200/JCO.2013.49.2678
pubmed: 23715580
pmcid: 5321083
Stein DM, Victorson DE, Choy JT, Waimey KE, Pearman TP, Smith K et al (2014) Fertility preservation preferences and perspectives among adult male survivors of pediatric cancer and their parents. J Adolesc Young Adult Oncol 3(2):75–82. https://doi.org/10.1089/jayao.2014.0007
doi: 10.1089/jayao.2014.0007
pubmed: 24940531
pmcid: 4048980
Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr et al (2014) First international consensus guidelines for breast cancer in young women (BCY1). Breast 23(3):209–220. https://doi.org/10.1016/j.breast.2014.03.011
doi: 10.1016/j.breast.2014.03.011
pubmed: 24767882
Dewald SR, Natarajan L, Su I (2017) Fertility preservation and decisional regret in young breast cancer survivors: a longitudinal analysis. J Clin Oncol 35(5):106. https://doi.org/10.1200/JCO.2017.35.5_suppl.106
doi: 10.1200/JCO.2017.35.5_suppl.106
Larsen EC, Müller J, Schmiegelow K, Rechnitzer C, Andersen AN (2003) Reduced ovarian function in long-term survivors of radiation-and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88(11):5307–5314. https://doi.org/10.1210/jc.2003-030352
doi: 10.1210/jc.2003-030352
pubmed: 14602766
Gardino SL, Jeruss JS, Woodruff TK (2010) Using decision trees to enhance interdisciplinary team work: the case of oncofertility. J Assist Reprod Genet 27(5):227–231. https://doi.org/10.1007/s10815-010-9413-8
doi: 10.1007/s10815-010-9413-8
pubmed: 20386978
pmcid: 2881204
Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE (2011) Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 205(2):103–110. https://doi.org/10.1016/j.ajog.2011.01.025
doi: 10.1016/j.ajog.2011.01.025
pubmed: 21411052
pmcid: 5111967
Society for Assisted Reproductive Technology, American Society for Reproductive Medicine (2004) Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 81(5):1207–1220. https://doi.org/10.1016/j.fertnstert.2004.01.017
doi: 10.1016/j.fertnstert.2004.01.017
Wallace WHB, Anderson RA, Irvine DS (2005) Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 6(4):209–218. https://doi.org/10.1016/s1470-2045(05)70092-9
doi: 10.1016/s1470-2045(05)70092-9
pubmed: 15811616
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS et al (2018) Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914
doi: 10.1200/JCO.2018.78.1914
pubmed: 29620997
Bann CM, Treiman K, Squiers L, Tzeng J, Nutt S, Arvey S et al (2015) Cancer survivors’ use of fertility preservation. J Womens Health 24(12):1030–1037. https://doi.org/10.1089/jwh.2014.5160
doi: 10.1089/jwh.2014.5160
Klock SC, Zhang JX, Kazer RR (2010) Fertility preservation for female cancer patients: early clinical experience. Fertil Steril 94(1):149–155. https://doi.org/10.1016/j.fertnstert.2009.03.028
doi: 10.1016/j.fertnstert.2009.03.028
pubmed: 19406395
Moravek MB, Confino R, Smith KN, Kazer RR, Klock SC, Lawson AK et al (2018) Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril 109(2):349–355. https://doi.org/10.1016/j.fertnstert.2017.10.029
doi: 10.1016/j.fertnstert.2017.10.029
pubmed: 29338854
pmcid: 5815903
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J et al (2017) Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat 165(1):151–159. https://doi.org/10.1007/s10549-017-4288-3
doi: 10.1007/s10549-017-4288-3
pubmed: 28503722
Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35. https://doi.org/10.1093/oxfordjournals.epirev.a036102
doi: 10.1093/oxfordjournals.epirev.a036102
pubmed: 8405201
Sonmezer M, Oktay K (2006) Fertility preservation in young women undergoing breast cancer therapy. Oncologist 11(5):422–434. https://doi.org/10.1634/theoncologist.11-5-422
doi: 10.1634/theoncologist.11-5-422
pubmed: 16720842
Samavat H, Kurzer MS (2015) Estrogen metabolism and breast cancer. Cancer Lett 356(2):231–243. https://doi.org/10.1016/j.canlet.2014.04.018
doi: 10.1016/j.canlet.2014.04.018
pubmed: 24784887
Cole PA, Robinson CH (1990) Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 33(11):2933–2942
doi: 10.1021/jm00173a001
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347–4353. https://doi.org/10.1200/jco.2005.05.037
doi: 10.1200/jco.2005.05.037
pubmed: 15824416
Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H et al (2011) Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 9(1):85. https://doi.org/10.1186/1477-7827-9-85
doi: 10.1186/1477-7827-9-85
pubmed: 21693033
pmcid: 3150251
Reddy J, Oktay K (2012) Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 98(6):1363–1369. https://doi.org/10.1016/j.fertnstert.2012.09.022
doi: 10.1016/j.fertnstert.2012.09.022
pubmed: 23058686
Turan V, Bedoschi G, Moy F, Oktay K (2013) Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 100(6):1681–5.e1. https://doi.org/10.1016/j.fertnstert.2013.08.030
doi: 10.1016/j.fertnstert.2013.08.030
pubmed: 24055050
pmcid: 3888552
Oktay K, Turan V, Kim J (2015) Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer. J Clin Oncol 33(15):9521
doi: 10.1200/jco.2015.33.15_suppl.9521
Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 33(22):2424–2429. https://doi.org/10.1200/JCO.2014.59.3723
doi: 10.1200/JCO.2014.59.3723
pubmed: 26101247
pmcid: 4507464
Allen PB, Pavone ME, Smith KN, Kazer R, Rademaker AW, Lawson AK et al (2018) The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience. Br J Haematol 180(6):901–904. https://doi.org/10.1111/bjh.14466
doi: 10.1111/bjh.14466
pubmed: 27982421
Akel RA, Guo XM, Moravek MB, Confino R, Smith KN, Lawson AK et al (2020) Ovarian stimulation is safe and effective for patients with gynecologic cancer. J Adolesc Young Adult Oncol 9(3):367–374. https://doi.org/10.1089/jayao.2019.0124
doi: 10.1089/jayao.2019.0124
pubmed: 31923372
Pavone ME, Innes J, Hirshfeld-Cytron JE, Kazer R, Zhang J (2011) Comparing thaw survival, implantation and live birth rates from cryopreserved zygotes, embryos and blastocysts. J Hum Reprod Sci 4(1):23–28. https://doi.org/10.4103/0974-1208.82356
doi: 10.4103/0974-1208.82356
pubmed: 21772736
pmcid: 3136065
Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101(4):1364–1371. https://doi.org/10.1210/jc.2015-3878
doi: 10.1210/jc.2015-3878
pubmed: 26751194
pmcid: 4880171
Goldrat O, Gervy C, Englert Y, Delbaere A, Demeestere I (2015) Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Hum Reprod 30(9):2184–2189. https://doi.org/10.1093/humrep/dev155
doi: 10.1093/humrep/dev155
pubmed: 26109617
Shapira M, Raanani H, Meirow D (2015) IVF for fertility preservation in breast cancer patients: efficacy and safety issues. J Assist Reprod Genet 32(8):1171–1178. https://doi.org/10.1007/s10815-015-0519-x
doi: 10.1007/s10815-015-0519-x
pubmed: 26126877
pmcid: 4554381
Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A et al (2006) Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91(10):3885–3890. https://doi.org/10.1210/jc.2006-0962
doi: 10.1210/jc.2006-0962
pubmed: 16882752
Domingo J, Guillén V, Ayllón Y, Martínez M, Muñoz E, Pellicer A et al (2012) Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97(4):930–934. https://doi.org/10.1016/j.fertnstert.2012.01.093
doi: 10.1016/j.fertnstert.2012.01.093
pubmed: 22283969
Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P (2013) Is Letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 29(11):993–996. https://doi.org/10.3109/09513590.2013.819083
doi: 10.3109/09513590.2013.819083
pubmed: 24000936
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 34(9):927–935. https://doi.org/10.1200/JCO.2015.62.3504
doi: 10.1200/JCO.2015.62.3504
pubmed: 26786933
pmcid: 4933127
Wangchinda P, Ithimakin S (2016) Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol 14(1):223. https://doi.org/10.1186/s12957-016-0988-0
doi: 10.1186/s12957-016-0988-0
pubmed: 27557635
pmcid: 4995804